With 0.3 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.44 million shares. During the session, the Education & Training Services company that operates in wider Consumer Defensive sector, reached to the highest price of $25.55 whereas the lowest price it dropped to was $25.18. The 52-week range on UTI shows that it touched its highest point at $26.71 and its lowest point at $12.14 during that stretch. It currently has a 1-year price target of $26.60. UTI paid its most recent dividend on 1458172800, while the ex-dividend date for that was 1458172800. Beta for the stock currently stands at 1.45.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of UTI was down-trending over the past week, with a drop of -1.75%, but this was down by -1.41% over a month. Three-month performance surged to 62.24% while six-month performance rose 58.77%. The stock gained 101.92% in the past year, while it has lost -1.75% so far this year. A look at the trailing 12-month EPS for UTI yields 0.74 with Next year EPS estimates of 1.22. For the next quarter, that number is 0.18. This implies an EPS growth rate of 29.33% for this year and 25.57% for next year.
Float and Shares Shorts:
At present, 53.82 million UTI shares are outstanding with a float of 49.75 million shares on hand for trading. On 2024-10-31, short shares totaled 1.86 million, which was 345.0 higher than short shares on 1727654400. In addition to Mr. Jerome A. Grant as the firm’s CEO & Director, Mr. Christopher E. Kevane J.D. serves as its Executive VP, Chief Legal Officer & Secretary.
Institutional Ownership:
Through their ownership of 0.88004 of UTI’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-06-30, UTI reported revenue of $196358000.0 and operating income of $26022000.0. The EBITDA in the recently reported quarter was $40792000.0 and diluted EPS was $nan.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for UTI since 3 analysts follow the stock currently. There are 3 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With UTI analysts setting a high price target of 30.0 and a low target of 22.0, the average target price over the next 12 months is 26.6. Based on these targets, UTI could surge 18.76% to reach the target high and fall by -12.91% to reach the target low. Reaching the average price target will result in a growth of 5.3% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of $0.71635 being high and $0.69835 being low. For UTI, this leads to a yearly average estimate of $0.70833.
